** Shares of drugmaker Regeneron REGN.O fall 13.28% to $525 premarket
** Company and partner Sanofi SASY.PA say their experimental drug, itepekimab, failed in one late-stage trial testing it for a lung disease commonly called "smoker's lung", but met the goal of another trial
** Sanofi's U.S.-listed shares down ~6.5% before the bell
** Itepekimab was being tested in former smokers in two studies for chronic obstructive pulmonary disease, a condition that mostly affects smokers but can also be caused by pollutants
** Both trials were testing if the drug was statistically significant in reducing moderate or severe flare-ups of the condition in former smokers
** Companies are assessing the data and will discuss next steps with regulatory authorities
** REGN shares down ~15% YTD
(Reporting by Manas Mishra in Bengaluru)
((Manas.Mishra@thomsonreuters.com; www.twitter.com/Manaswrites15;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.